FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Milly De Jonge

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Corine Ekhart; Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Milly E De Jonge; Alwin D R Huitema; Jos H Beijnen; Sjoerd Rodenhuis
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Milly De Jonge (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Corine Ekhart; Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6502-8.
2006: Milly E De Jonge; Alwin D R Huitema; Jos H Beijnen; Sjoerd Rodenhuis
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
British journal of cancer 2006;94(9):1226-30.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Therapeutic drug monitoring 2005;27(6):756-65.
2005: Milly E De Jonge; Alwin D R Huitema; Marjo J Holtkamp; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
Cancer chemotherapy and pharmacology 2005;56(4):370-8.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
Therapeutic drug monitoring 2005;27(3):393-402.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
Cancer chemotherapy and pharmacology 2005;55(5):507-10.
2005: Milly E De Jonge; Alwin D R Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
British journal of clinical pharmacology 2005;59(3):325-34.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
Anti-cancer drugs 2005;16(3):331-6.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Clinical pharmacokinetics of cyclophosphamide.
Clinical pharmacokinetics 2005;44(11):1135-64.
2005: Milly E De Jonge; Alwin D R Huitema; Annemarie C Tukker; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):273-83.
2005: Anthe S Zandvliet; Alwin D R Huitema; Milly E De Jonge; Rob den Hoed; Rolf W Sparidans; Vincent M Hendriks; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Basic & clinical pharmacology & toxicology 2005;96(1):71-9.
2005: Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Clinical pharmacokinetics 2005;44(2):147-73.
2004: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Journal of pharmacokinetics and pharmacodynamics 2004;31(2):135-56.
2004: Milly E De Jonge; H J G Desirée van den Bongard; Alwin D R Huitema; Ron A A Mathôt; Hilde Rosing; Paul Baas; nico van zandwijk; Jos H Beijnen; Jan H M Schellens
Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2237-44.
2004: Milly E De Jonge; Selma M Van Dam; Michel J X Hillebrand; Hilde Rosing; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):262-71.
2003: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.
Therapeutic drug monitoring 2003;25(3):261-3.
2002: Milly E De Jonge; Ron A A Mathôt; Otilia Dalesio; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
Bone marrow transplantation 2002;30(9):593-7.
2002: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
Cancer chemotherapy and pharmacology 2002;50(3):251-5.